Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19 Supply of hydroxychloroquine (HCQ) from Novartis will co…
As the world grapples with the COVID-19 pandemic, we need to continue our efforts to support vulnerable populations, who may be more at risk, such as people with sickle cell disease (SCD).Sickle cell disease is a hereditary and life-threatening conditi…
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers acro…
FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum There are an estimated 2.7…
UNICEF warns that an additional 6 000 children under five1 could die every day, without urgent action. On this Day of the African Child, Novartis remains committed to the health and wellbeing of Africa’s children.An African child is 8 times more likely…
We believe unequivocally that Black Lives Matter.As a company focused on improving human health globally, we also recognize the disparities Black communities and communities of color face when it comes to health care. Our teams are working to ensure ou…
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The update includes characterization of adverse events, retinal …
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma1.Am…
Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA is the fourth EU indication for Cosentyx, providing patient…
We each have a story to tell. A community that contributes to who we are today. Heroes who hold us up in the face of challenges.Our stories are what make us exceptional – they inspire those around us but also future generations. At Novartis, we want…
